ArticleCell2018
5-HT
Abstract read
In one paragraph
Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers.
0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
115 citing papers in PubMed.
- Atomic, structural and molecular insights into GPCR ligand binding and signalling.Nature reviews. Molecular cell biology · 2026Review
- Structure-based design of subtype-selective psychedelic analogs.Nature communications · 2026Article
- ScrambleBench: a workflow for comparative assessment of structure-based de novo generative models.Journal of cheminformatics · 2026Article
- Dynamic mechanism for subtype selectivity of endocannabinoids.The Journal of biological chemistry · 2026Article
- Neuroprotective Potential of Pinostrobin in a Rat Model of Huntington's Disease: Behavioural, Biochemical, and Molecular Docking Evidence.Molecular neurobiology · 2026Article
- A structural overview of G-protein-coupled receptors in neurological disorders.Acta pharmacologica Sinica · 2026Review
- Article
- Coumarin benzamide scaffold as potential 5-HTJournal of molecular modeling · 2025Article
- Discovery of Highly Selective 5-HTJournal of medicinal chemistry · 2025Article
- Psychedelic compounds directly excite 5-HTTranslational psychiatry · 2025Article
- Integration of machine learning and experimental validation reveals new lipid-lowering drug candidates.Acta pharmacologica Sinica · 2025Article
- Pharmacological Characterization of the Novel CRF1 Receptor Antagonist, Thiazolo[4,5-d] Pyrimidine Analog, M43.Biomolecules · 2025Article
- Biased signalingActa pharmaceutica Sinica. B · 2025Review
- Novel 4,5-Dihydrothiazole-Phenylpiperazine Derivatives: Synthesis, Docking Studies and Pharmacological Evaluation as Serotonergic Agents.ChemMedChem · 2025Article
- Applications of artificial intelligence in drug discovery for neurological diseases.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- 5-HTPharmacological reviews · 2025Review
- Diazepine Agonists of the 5-HTJournal of medicinal chemistry · 2025Article
- Antifungal Structure-Activity Relationship Studies of Broad-Spectrum Phenothiazines.ACS omega · 2025Article
- Ablation of Hepatic Asah1 Gene Disrupts Hepatic Lipid Homeostasis and Promotes Fibrotic Nonalcoholic Steatohepatitis in Mice.The American journal of pathology · 2025Article
- Uncovering the unique characteristics of different groups of 5-HTPharmacological reports : PR · 2024Article
55 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Yao PengiHuman Institute, ShanghaiTech University, Shanghai 201210, China; Yunnan Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Molecular and Clinical Medicine, Kunming Medical University, Kunming 650500, China; National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
John D McCorvyDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Kasper HarpsøeDepartment of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
Katherine LansuDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Shuguang YuanLaboratory of Physical Chemistry of Polymers and Membranes, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH B3 495 (Bâtiment CH) Station 6, Lausanne 1015, Switzerland.
Petr PopovDepartments of Biological Sciences and Chemistry, Bridge Institute, Michelson Center, University of Southern California, Los Angeles, CA 90089, USA; Moscow Institute of Physics and Technology, Dolgoprudny 141700, Russia.
Lu QuiHuman Institute, ShanghaiTech University, Shanghai 201210, China; National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Mengchen PuiHuman Institute, ShanghaiTech University, Shanghai 201210, China.
Tao CheDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Louise F NikolajseniHuman Institute, ShanghaiTech University, Shanghai 201210, China; Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
Xi-Ping HuangDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP), University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Yiran WuiHuman Institute, ShanghaiTech University, Shanghai 201210, China.
Ling SheniHuman Institute, ShanghaiTech University, Shanghai 201210, China; School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Walden E Bjørn-YoshimotoDepartment of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
Kang DingiHuman Institute, ShanghaiTech University, Shanghai 201210, China; School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Daniel WackerDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Gye Won HanDepartments of Biological Sciences and Chemistry, Bridge Institute, Michelson Center, University of Southern California, Los Angeles, CA 90089, USA.
Jianjun ChengiHuman Institute, ShanghaiTech University, Shanghai 201210, China.
Vsevolod KatritchDepartments of Biological Sciences and Chemistry, Bridge Institute, Michelson Center, University of Southern California, Los Angeles, CA 90089, USA; Moscow Institute of Physics and Technology, Dolgoprudny 141700, Russia.
Anders A JensenDepartment of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
Michael A HansonGPCR Consortium, San Marcos, CA 92078, USA.
Suwen ZhaoiHuman Institute, ShanghaiTech University, Shanghai 201210, China; School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
David E GloriamDepartment of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
Bryan L RothDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP), University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: bryan_roth@med.unc.edu.
Raymond C StevensiHuman Institute, ShanghaiTech University, Shanghai 201210, China; Departments of Biological Sciences and Chemistry, Bridge Institute, Michelson Center, University of Southern California, Los Angeles, CA 90089, USA; School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China. Electronic address: stevens@shanghaitech.edu.cn.
Zhi-Jie LiuiHuman Institute, ShanghaiTech University, Shanghai 201210, China; Yunnan Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Molecular and Clinical Medicine, Kunming Medical University, Kunming 650500, China; National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China; School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China. Electronic address: liuzhj@shanghaitech.edu.cn.
Funding
Project 3U54GM094618 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI STEVENS, RAYMOND C · 2010 to 2014
$17.1MScreening CoreU19MH082441 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CARON, MARC G., WETSEL, WILLIAM C · 2007 to 2016
$15.2MMolecular Details of Psychoactive Drug ActionsR01MH112205 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Bryan L. Roth, Brian K Shoichet · 2017 to 2026
$6.1MNIGMS NIH HHS U54 GM094618NIMH NIH HHS R01 MH112205NIMH NIH HHS U19 MH082441
Abstract
Drugs frequently require interactions with multiple targets-via a process known as polypharmacology-to achieve their therapeutic actions. Currently, drugs targeting several serotonin receptors, including the 5-HT
Indexed as
ErgotamineHEK293 CellsHumansObesityProtein DomainsReceptor, Serotonin, 5-HT2CRitanserinSchizophreniaSerotonin 5-HT2 Receptor AgonistsSerotonin 5-HT2 Receptor AntagonistsStructure-Activity RelationshipSubstance-Related DisordersErgotamineReceptor, Serotonin, 5-HT2CRitanserinSerotonin 5-HT2 Receptor AgonistsSerotonin 5-HT2 Receptor Antagonistscrystal structuresergotamineGPCRpolypharmacologyritanserinselectivityserotonin 2C receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.